How Do Docs Learn About New Drugs? TV, Of Course

If asked, some will equivocate and say they get their facts from medical journals and from published studies, but never from those pesky misleading ads.

How to Shatter the Glass Ceiling

Healthcare marketing has a head start in grooming women leaders. But it's by no means a fait accompli.

Who Needs a Gold Watch, Anyway?

Perhaps we should always bear in mind the need to periodically reinvigorate and reshape our careers.

Quitting Your Job: Dramatic Exit or Inappropriate?

Apologies to Paul Simon, but there must be 50 ways to leave your employer.

When It Comes to the FDA, Does It All Come Down to Money?

In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?

Is the Trump Administration the Cure the FDA Needs?

Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.

Harness the Power of Paranoia to Disrupt Your Business

In short, CEOs can't be afraid to walk away from their most profitable line if another approach may lead to improved long-term outcomes.

Paying Lip Service to STEM Isn't Enough

I'm not suggesting that colleges become vocational schools. But don't you think they should also help young people prepare for the life they're going to be living?

Will Investors Reward Drugmakers That Limit Price Increases?

Now here comes the big question. Will the shareholders and directors of KaloBios and Allergan reward or punish their CEOs for what some may see as revenue-capping concessions?

How About a Moon Shot for Orphan Diseases?

You can see it everywhere: on TV and in newspapers and ads. The decades of struggle against cancer are paying off.

Moving Forward — Without the Promotion

Until now, your superiors have promoted you. Now it's your responsibility to show why you belong.

Why are We Still Shortchanging Women in the Workplace?

Why would any CEO tolerate a corporate culture that holds people back?

Zika Crisis Stresses Need for Pharma Industry

When pharmaceutical companies are needed, we're Jonas Salks; when we ask to be paid, we're Martin Shkrelis.

Right-to-Try Laws Take Sensible Approach to Reforming FDA Rules

The regulator's reliance on double-blind, placebo-controlled trials with exhaustive inclusion and exclusion criteria is incompatible with today's precision medicine.

Your PharmaScope 2016

If we don't clean up our act and do something about predatory pricing scandals, we'll wind up with Washington bureaucrats telling us what we can charge for our products.

A Company's Culture Begins on Day One

If we were going to be one of a kind, we needed a staff that understood and had lived through what our clients were facing.

A Faster FDA Approval Rate Key to Price Debate

Apparently, Dr. Ezekiel Emanuel loves to open his window and shout "fire!"

Back Talk: Who's Aiming for the Feet?

That 700% price hike created an issue that threatens years of pharma progress

Back Talk: Hail to the . . . CEO?

Back Talk: Is Cost Myopia Unfocused?

Before you fire up your outrage and vent your spleen, take a long look inside your parents' (or your own) medicine chest

Leadership and Truth

In Jack Welch's view, one of the worst mistakes a manager can make is . . .

Back Talk: In a Jam? Do the Right Thing

A textbook example of a firm doing the right thing in a crisis: J&J's decisive crisis management saved a brand

Who Will Pay the Piper?

Robbing pharma to pay Senator Pothole will not encourage innovation

Back Talk: Eyes up, I'm talking to you!

Your move? Lean in and make eye contact. Show that you care

Back Talk: Lonely at the top?

Being in charge does not mean that you need to make every decision

Phone-free connections?

At any well-run business meeting, a smartphone is not only disruptive but also signals that its user is less than fully engaged with the business at hand

Who's Calling Who "Murky"?

Once we venerated doctors. Now we question every dollar they make

Give Docs a Shot in the Arm

Is there anything that pharma can do to make doctors' lives easier?

Predicting Your Pink Slip

Any time a firm needs to save money, high-salaried executives are targets

Pharma's Role in Cost Control

It may be time to adopt a model in which we help deliver healthcare

Think You Own Your Brand? Think Again

When you have a successful brand, you tamper with it at your peril

The $3 Generic and the $1,000 Pill: Pharma Outsiders Just Don't Get it

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Making medicine emotional

We identify not with just the product, but with what it represents

Popping the digital bubble

A general consensus is that a "shake-up" of some kind is coming

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.

Putting moves on Big Data

It's time to make healthcare data Big, and for patients' sake, sexy

Agencies, get over your fear

Success cures fear, and success is born out of focus and hard work

From RFP to termination call

There is room for growth, loyalty and long-term partnering

How to raise the quality bar

As healthcare marketers and their agencies develop ever more digital customer solutions like mobile medical apps, it may be time to take a fresh look at these offerings

Is the current agency model a joke?

Why agencies must get out of the strategy business.

Strengthening digital DNA

Digital DNA is an inevitability, as we cannot forever resist this societal tide

It's all about the context

Contextual awareness can mobilize patients' relationships to a brand

What Deen could have done

In times of crisis, there is no sleep for the weary—or the accused

Idea still trumps everything

The octane of the idea determines how well a digital tactic performs

Off-label on the table

FDA cannot rely solely on the label or the current standard for drug approvals

Learning from BlackBerry

Apple picked up on what customers truly wanted, a more holistic experience

Marketers in white coats

A scientific approach to marketing could yield efficiencies at every stage

Shelter from the storm

The phrase "perfect storm" powerfully describes the colliding forces in healthcare

The multicultural moment

The question is not whether you should do it, but how to do it successfully

Learning from the e-lection

Mechanics may have been instrumental in determining the outcome of the election

Take off the blinders

"Big data" has radically enhanced the opportunities for industry to help patients

Rise, fall of the 'Mad Men' age

Project timelines that were once measured in months are now compressed into days

Putting content into context

As with "one-size-fits-all" marketing, the "content-only-driven" strategy is outdated

Pharma must reboot iPads

For pharma to truly unlock the power of the iPad, we need to evolve the way we look at it

Soldiers of communication

Military communication has an urgency that you can't match in the business world

Pharma, heal thyself

Improved patient outcomes must be a stated, and measured, goal of all players in the pharma industry

Closest to the customer wins

Agencies can embrace the need to change—or sit back and watch their value melt away

CES: Convergence continues

The desire to reduce the cost of delivering care has led to redefining 'point of care'

Docs, patients and pharma

Harnessing the power of digital and social media to maximize the doctor/patient relationship

Healthcare's tectonic shift

Whether or not Obamacare survives in court, the cost-control squeeze is going to intensify

Making sense of safety data

A tidal wave of information is on the horizon. Processing, analyzing and drawing accurate conclusions from that information is healthcare's next major challenge.

Getting on the digital track

Pharmaceutical companies have not moved nearly fast enough to keep up with their customers' digital preferences

What 1966 can still teach us

More than enough has been written how change is affecting our industry today. Instead, let's look at what hasn't changed and why the things that have not changed remain important.

Potential of physician CRM

A lot of ink has been spilt on the decline of the blockbuster and the search for a new specialty-product commercial model. But less attention has been paid to how that changes marketing strategy.

Social health revolution

While doctors and nurses remain the first choice for most people with health concerns, the internet is making a significant impact on patients' healthcare decisions.

A view to a pill

Many individuals outside the pharma industry have a maniacal vision of our senior executives.

Multicultural matters

It will take some time before we begin to see top-line results from the 2010 US Census. However, it's a pretty safe prediction that the new census will show us that we are at or near the point where more than one out of every three of the more than 300 million Americans did not designate themselves as white.

Moms on the front line

On Feb. 28, more than 30 countries across the world observed Rare Disease Day.

The traditional model is N/A

For generations, success in pharma could be virtually guaranteed by the three Ms: Put your best minds on discovering new treatments, invest enough money in development and commercialization and support the resulting brands with enough marketing, and you were golden.

The real story at CES 2011

Innovations in healthcare seem to be popping up in new places all the time, including the Consumer Electronics Show (CES) in January.

Keep fighting for free speech

It dawned on me at the New Year, that it was some 20 years ago that the Coalition for Healthcare Communication came into being.

The changing role of brands

A brand is more than just a symbol, slogan or trade name. It transcends logos and visual identities. Brands establish identity, provide differentiation and, most importantly, drive economic value.

The vital signs of culture

As our nation continues to debate how the healthcare system should be fixed, little attention has been paid to the need to better incorporate multiculturalism in the provision of medical care.

Nurture advocacy relationships

Advocacy organizations serve as primary drivers of opinion and knowledge with patients, media and policy makers.

Next innovation is performance

In the 1990s, brand-based DTC advertising was a big breakthrough innovation in pharmaceutical marketing.

The doctor won't see you now

The number of pharma sales reps who wait for doctors and never see them is quickly growing.

Boomers respond to DRTV

Call it the Gray Tsunami, the Silver Tsunami or just plain Baby Boomers getting old. The first of more than 77 million Baby Boomers entering Medicare next year will lead to more changes in our ever-evolving healthcare system.

The role of communications

The biggest piece of social legislation since Medicare has passed. The sweeping healthcare reform bill will touch the lives of all Americans, and even more so for the 34 million who will now have health insurance.

The time is now

Anyone who is involved with the biopharmaceutical industry and who is even half-awake knows how difficult it is for companies to navigate today's increasingly hostile legal and regulatory enforcement landscape.

Marketers lack leadership

Many people regard pharmaceutical firms as a necessary evil—they deliver life-saving products but are also to blame for rising healthcare costs. With the industry facing subsequent and serious image problems, strong leadership matters more than ever.

The industry's cultural deficit

Innovative chemical compounds have improved the quality and longevity of the lives of many Americans. Many diseases that were once a death sentence are now treatable.

The pharma PR dilemma

Call it the law of unintended consequences or the perfect storm or a bad hair day or any other cliché you can think of, but as 2009 came to a close we once again faced a cluster of bad news for the pharma industry.

10 predictions for the decade

The pharma industry looks to the next decade with trepidation. Growth in many sectors is flat. Generic expiries loom. Trust in the industry is at rock bottom.

Warranties for healthcare?

American consumers are used to warranties. If you buy a TV set and it stops working within a specified time, you can ask for a replacement or to have it fixed.

Social media virgin at work

I'm old enough to remember a time when everybody in pharma suddenly had to have a website for their brand—not for any strategic reason, but because it was the thing to do.

Death of the public option

Mr. Ross, when you headed KPR Informedia, did you submit articles to medical journals that were ghostwritten?

DDMAC losing patience

In its August 2009 blizzard of compliance correspondence, DDMAC used some of the harshest language in recent Warning Letter memory to send what can only be interpreted as a message that its patience is wearing thin.

Is pharma ready this time?

Pharma and biotech companies are competing to have enough vaccine on hand for the next swine flu (H1N1) outbreak. They missed the one last winter and spring, and their response has uniformly been: We'll be ready next time.

Social media rules for pharmas

At a recent conference, I told two perplexed-looking FDA attendees that I thought pharma has a distinct advantage with social media, because we're used to marketing with boundaries, and social-media rules and FDA guidelines are actually quite similar.

Latest FDA guidance may require copy testing

What the FDA euphemistically calls "guidances" are usually received by industry with something less than cheers. Despite the name, the guidances are often perceived as directives to be ignored at your peril.

Old ideas for the new world

My friend and former colleague, the late Steve Gross, was having dinner one night with the head of rheumatology from a major teaching hospital. 
The doctor asked Steve if he knew the "Five Rules for Success."

The magic of IT

Again and again you see the statement that information technology will not only avoid medication errors but stop (or even reverse) the upward trend of healthcare costs.

Tune up for tough times

In these troubled times, it is important to remember that some things are within your control, while others are not. Troughs in the economic cycle provide an opportunity to assess where you are, decide where you want to be and develop a plan for getting there.

The dilemma of the pens

As of the first of the year the Pharmaceutical Research and Manufacturers of America (PhRMA code) forbade the distribution of such goodies as pens or mugs with product logos.

Good job

I remember the pleasure I took in watching my children learn to climb stairs.

Clarifying myth-information

By the time you read this, most of the holiday parties will be a distant memory. The champagne is gone, the confetti swept up and the sugar plums have turned into prunes.

Notes from rehab

No, not that kind of rehab. On October 4 I had a stroke.

Pens and doughnuts

Disclosure: My father and mother were both physicians so I obviously have a pro-doctor bias.